A recent propensity-matched analysis from the HF Adherence and Retention Trial showed that sodium restriction to <2.5 g/d in NYHA class II/III HF patients is associated with a 72% higher risk of death or HF hospitalization compared to a higher sodium intake of >2.5 g/d, especially in patients not receiving therapy with renin–angiotensin antagonists with a hazard ratio of 5.23 [61]. Here, REN is linked to hydrops fetalis.